GO:0086008 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0086008 describes the voltage-gated potassium channel activity that drives the repolarization phase of the cardiac muscle cell action potential.
• The main molecular players are Kv11.1 (hERG/KCNH2), Kv7.1 (KCNQ1), Kv1.5 (KCNA5), and Kv4.3 (KCND3), which together shape action potential duration.
• Loss- or gain-of-function of these channels causes long QT syndrome, short QT syndrome, and arrhythmias, making them prime drug-safety and disease-modeling targets.
• hERG (KCNH2) is the most studied cardiac repolarizing channel because drug-induced block of hERG is a major cause of acquired long QT syndrome.
• CRISPR knockout, point-mutation, and knock-in models in human stem cell-derived cardiomyocytes enable precise dissection of channel function in repolarization.
• Studying GO:0086008 requires a combination of electrophysiology, computational modeling, and gene-editing approaches to link molecular activity to clinical phenotypes.
Description
The cardiac action potential is a tightly orchestrated electrical signal whose repolarization phase depends on the coordinated activity of multiple voltage-gated potassium channels. GO:0086008, voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization, captures the molecular function of potassium channels that open in response to membrane depolarization and allow potassium ions to flow out of the cardiac muscle cell, thereby restoring the resting membrane potential. This activity is essential for normal heart rhythm, and its disruption is directly linked to life-threatening arrhythmias. Researchers study this term to understand how individual channel subunits contribute to repolarization, how mutations alter channel gating, and how pharmacological agents modulate these currents. Because many drugs inadvertently block cardiac potassium channels, particularly hERG, this GO term is also central to cardiac safety pharmacology. The availability of human pluripotent stem cell-derived cardiomyocytes and CRISPR gene-editing tools has made it possible to model patient-specific channel mutations and to test targeted interventions. This article synthesizes the current understanding of GO:0086008, its gene players, regulatory mechanisms, disease associations, and the experimental methods used to investigate it.
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization At A Glance
| GO ID | GO:0086008 |
|---|---|
| GO term | voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Voltage-dependent potassium ion transport across the cardiac muscle cell plasma membrane during action potential repolarization |
| Major genes | KCNH2 (hERG/Kv11.1), KCNQ1 (Kv7.1), KCNA5 (Kv1.5), KCND3 (Kv4.3) |
| Cellular location | Plasma membrane of cardiac muscle cells |
| Associated diseases | Long QT syndrome, short QT syndrome, drug-induced arrhythmia |
| Research methods | Patch-clamp electrophysiology, computational modeling, CRISPR gene editing, stem cell-derived cardiomyocytes |
What Is GO:0086008?
GO:0086008 is a molecular function term defined as enabling the transmembrane transfer of a potassium ion by a voltage-gated channel through the plasma membrane of a cardiac muscle cell, contributing to the repolarization phase of an action potential. A voltage-gated channel is one whose open state depends on the voltage across the membrane in which it is embedded. In simpler terms, it is the activity of potassium channels that respond to electrical changes in heart muscle cells and help the cells reset after each beat.
Why Is voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization Important in Cell Biology?
GO:0086008 is critically important because repolarization of the cardiac action potential is a prerequisite for every normal heartbeat, and failure of this process leads to arrhythmias that can cause sudden cardiac death. The channels underlying this activity are also the primary targets for drug-induced cardiotoxicity, making them a central focus in pharmaceutical safety assessment. Understanding the molecular details of these channels helps researchers design safer drugs, interpret genetic variants, and develop patient-specific models of cardiac channelopathies.
• Repolarization determines action potential duration and the QT interval on the electrocardiogram, a key clinical readout.
• hERG (KCNH2) block by drugs is a leading cause of acquired long QT syndrome and drug withdrawal from the market.
• Mutations in KCNQ1 and KCNH2 cause congenital long QT syndrome types 1 and 2, respectively.
• Kv1.5 and Kv4.3 contribute to atrial and ventricular repolarization and are targets for antiarrhythmic drugs.
• Cardiac potassium channels are modulated by natural products, creating both therapeutic opportunities and toxicity risks.
• Human induced pluripotent stem cell-derived cardiomyocytes with CRISPR-edited channel genes provide a platform for disease modeling and drug testing.
• Computational models of hERG structure and function aid in predicting drug binding and gating defects.
• Intracellular trafficking and maturation of hERG protein are regulated processes that affect repolarization capacity.
• TBX20 controls KCNH2 expression, linking transcriptional regulation to repolarization function.
• Understanding these channels supports the development of precision medicine approaches for inherited arrhythmia syndromes.
What Happens During voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization?
Phase 0: Depolarization triggers voltage sensing
In simple terms: When the heart cell fires, the voltage inside the cell becomes positive, and this change is sensed by potassium channels.
During the upstroke of the cardiac action potential, sodium and calcium channels depolarize the membrane, causing the inside of the cell to become positive. This depolarization is detected by the voltage-sensing domains of potassium channels such as Kv11.1 (hERG) and Kv7.1 (KCNQ1), which begin to transition from a closed to an open state. The voltage-dependent gating of these channels is a fundamental property that links electrical excitation to potassium efflux.
Phase 1 and 2: Early repolarization and plateau
In simple terms: Some potassium channels open briefly to start the reset, while others stay closed until later.
Transient outward potassium currents, mediated by channels such as Kv4.3 (KCND3), contribute to early phase 1 repolarization. During the plateau phase (phase 2), calcium influx balances potassium efflux, and the delayed rectifier channels, including Kv7.1 and Kv11.1, begin to activate slowly. The ultrarapid delayed rectifier current, carried by Kv1.5 (KCNA5), also contributes to repolarization in atrial cells.
Phase 3: Rapid repolarization
In simple terms: Potassium channels open wide, letting potassium rush out to bring the voltage back down.
The rapid repolarization phase is driven by the opening of voltage-gated potassium channels, particularly hERG (Kv11.1) and Kv7.1, which conduct large outward potassium currents. hERG channels have unusual gating properties, including fast inactivation, which paradoxically allows them to conduct more current during repolarization. This phase restores the resting membrane potential and is essential for the heart to be ready for the next beat.
Phase 4: Return to resting state
In simple terms: Once the cell is reset, the potassium channels close again, and the cell waits for the next signal.
After repolarization, the potassium channels close, and the cell returns to its resting membrane potential. Some channels, such as Kv1.5, may remain partially active to maintain the resting potential in atrial cells. The proper closing of these channels prevents excessive potassium efflux and ensures electrical stability.
Key Genes Involved in GO:0086008 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization
The following genes encode the principal voltage-gated potassium channel subunits and regulatory proteins that contribute to GO:0086008.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KCNH2 | Encodes Kv11.1 (hERG), the rapid delayed rectifier potassium channel | Primary target for drug-induced long QT syndrome; mutations cause LQT2 |
| KCNQ1 | Encodes Kv7.1, the slow delayed rectifier potassium channel | Mutations cause LQT1 and short QT syndrome; important for repolarization reserve |
| KCNA5 | Encodes Kv1.5, an ultrarapid delayed rectifier channel | Contributes to atrial repolarization; target for antiarrhythmic drugs |
| KCND3 | Encodes Kv4.3, a transient outward potassium channel | Mediates early repolarization; involved in Brugada syndrome and atrial fibrillation |
| KCNE1 | Encodes MinK, a beta subunit that modulates Kv7.1 | Modifies KCNQ1 gating and drug sensitivity |
| KCNE2 | Encodes MiRP1, a beta subunit that modulates hERG | Modulates hERG function and drug response |
| TBX20 | Transcription factor controlling KCNH2 expression | Regulates hERG channel levels; mutations linked to cardiac defects |
| KCNJ2 | Encodes Kir2.1, a inward rectifier potassium channel | Maintains resting potential; mutations cause Andersen-Tawil syndrome |
| KCNJ12 | Encodes Kir2.2, another inward rectifier | Contributes to resting membrane potential |
| SCN5A | Encodes Nav1.5, the cardiac sodium channel | Mutations cause Brugada and long QT syndrome type 3; interacts with repolarization |
| CACNA1C | Encodes Cav1.2, the L-type calcium channel | Calcium influx during plateau influences repolarization timing |
| CALM1 | Encodes calmodulin, a calcium sensor | Regulates calcium-dependent modulation of potassium channels |
| AKAP9 | A-kinase anchoring protein 9 | Scaffolds signaling complexes that regulate potassium channel phosphorylation |
| KCNE3 | Encodes MiRP2, a beta subunit | Modulates Kv7.1 and other channels |
| KCNE4 | Encodes MiRP3, a beta subunit | Modulates Kv4.3 and other channels |
| KCNE5 | Encodes MiRP4, a beta subunit | Modulates Kv4.3 and Kv7.1 |
| KCNIP2 | Encodes KChIP2, a calcium-binding accessory protein | Regulates Kv4.3 trafficking and gating |
| KCNH6 | Encodes Kv11.2, a hERG-related channel | Contributes to repolarization in some species |
How Is voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization Regulated?
The activity of voltage-gated potassium channels involved in cardiac repolarization is regulated at multiple levels. Transcriptional control includes TBX20, which directly regulates KCNH2 expression and thus hERG channel levels. At the protein level, channel trafficking and maturation are modulated by intracellular pathways; for example, rosuvastatin decreases mature hERG protein expression on the membrane through an intracellular mechanism. Beta subunits such as KCNE1 and KCNE2 alter gating kinetics and drug sensitivity. Phosphorylation by kinases and interaction with scaffolding proteins like AKAP9 further tune channel activity. Additionally, calcium-calmodulin signaling modulates channel gating in response to changes in intracellular calcium. These regulatory layers ensure that repolarization is matched to heart rate and metabolic demands.
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNH2 | Long QT syndrome type 2, drug-induced arrhythmia | CRISPR knockout or point-mutation in hiPSC-derived cardiomyocytes |
| KCNQ1 | Long QT syndrome type 1, short QT syndrome | KCNQ1-deficient hESC-derived cardiomyocytes |
| KCNA5 | Atrial fibrillation, repolarization abnormalities | Knockout or overexpression in atrial cardiomyocytes |
| KCND3 | Brugada syndrome, atrial fibrillation | Point-mutation knock-in in hiPSC-derived cardiomyocytes |
| KCNE1 | Long QT syndrome type 5, Jervell and Lange-Nielsen syndrome | Knock-in of patient mutations in stem cell models |
Long QT syndrome and arrhythmias
Loss-of-function mutations in KCNH2 (hERG) or KCNQ1 cause congenital long QT syndrome types 2 and 1, respectively, which are characterized by delayed repolarization and increased risk of torsades de pointes. Drug-induced block of hERG is a common cause of acquired long QT syndrome, leading to arrhythmias and sudden cardiac death. KCNQ1-deficient human embryonic stem cell-derived cardiomyocytes model QT prolongation and provide a platform for drug testing.
Short QT syndrome and gain-of-function channelopathies
Gain-of-function mutations in potassium channels can accelerate repolarization and cause short QT syndrome, another arrhythmia syndrome. These mutations highlight the importance of balanced potassium currents for normal cardiac electrical activity.
Drug cardiotoxicity and safety pharmacology
Many pharmacological agents, including natural products and synthetic drugs, block hERG and other cardiac potassium channels, leading to repolarization abnormalities. The hERG assay is a standard component of preclinical drug safety evaluation. Celecoxib, for example, blocks Kv1.5, Kv4.3, and Kv7.1 channels and affects cardiac action potentials. Rosuvastatin reduces mature hERG protein levels, illustrating that drug effects can occur through trafficking mechanisms.
Atrial fibrillation and repolarization remodeling
Kv1.5 (KCNA5) is an important determinant of atrial repolarization, and its dysfunction is implicated in atrial fibrillation. Kv4.3 (KCND3) also contributes to atrial and ventricular repolarization, and its modulation affects arrhythmia susceptibility. Understanding these channels aids in the development of atrial-selective antiarrhythmic drugs.
From voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KCNH2 abolish hERG current and prolong action potential? | CRISPR knockout of KCNH2 in hiPSC-derived cardiomyocytes |
| How does a specific KCNQ1 mutation alter channel gating? | Point-mutation knock-in of the mutation in hiPSC-derived cardiomyocytes |
| Can a fluorescent tag track hERG trafficking to the membrane? | Tagged knock-in of KCNH2 with a fluorescent protein |
| Does overexpression of TBX20 increase KCNH2 expression? | Overexpression of TBX20 in cardiac cell lines |
| Which beta subunits modulate Kv4.3 current? | Knockout of KCNE4 or KCNE5 in cardiomyocytes |
| Can a drug rescue trafficking-defective hERG mutants? | Knock-in of trafficking mutation and treatment with pharmacological chaperones |
How to Study the voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Ion currents through single channels or whole cells | Characterizing hERG, Kv7.1, Kv1.5, Kv4.3 currents |
| Computational modeling | Predictions of channel structure, gating, and drug binding | Virtual screening and mechanistic studies of hERG |
| hiPSC-derived cardiomyocytes | Action potential duration and arrhythmia phenotypes | Disease modeling of long QT syndrome |
| Western blot | Protein expression and maturation | Assessing hERG trafficking after drug treatment |
| Immunocytochemistry | Subcellular localization of channels | Visualizing channel distribution in cardiomyocytes |
| qRT-PCR | mRNA expression levels of channel genes | Measuring KCNH2 expression after TBX20 modulation |
| CRISPR gene editing | Precise genetic modifications | Creating knockout or knock-in models of channel genes |
| Action potential recording | Action potential duration and morphology | Evaluating repolarization defects in stem cell models |
Patch-clamp electrophysiology
Patch-clamp recordings are the gold standard for measuring voltage-gated potassium channel activity. They allow direct quantification of current amplitude, voltage dependence of activation and inactivation, and kinetics of repolarizing currents such as IKr and IKs. This method is used to characterize the effects of mutations and drugs on channel function.
Computational modeling and simulation
Computational models of hERG and other cardiac potassium channels integrate structural and electrophysiological data to predict drug binding, gating mechanisms, and effects on action potential duration. These models help prioritize compounds for safety testing and guide mutagenesis studies.
Stem cell-derived cardiomyocyte models
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a renewable source of human cardiac cells for studying repolarization. CRISPR-edited hiPSC-CMs carrying patient-specific mutations in KCNQ1 or KCNH2 recapitulate disease phenotypes such as prolonged action potentials and can be used for drug screening.
Biochemical and trafficking assays
Western blotting, immunocytochemistry, and surface biotinylation measure the expression, maturation, and membrane localization of potassium channel proteins. These assays are used to study how drugs like rosuvastatin affect hERG trafficking and how transcription factors like TBX20 regulate KCNH2 expression.
How CRISPR Can Be Used to Study GO:0086008 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization
Knockout
CRISPR knockout of KCNH2, KCNQ1, or other potassium channel genes in cardiomyocytes abolishes the corresponding current and prolongs action potential duration, providing causal evidence for the role of these channels in repolarization. Knockout models are also used to assess compensatory changes in other channels.
Point Mutation
Introducing patient-specific point mutations (e.g., in KCNQ1 or KCNH2) via CRISPR allows researchers to study how single amino acid changes alter channel gating, trafficking, and drug sensitivity. These models are valuable for genotype-phenotype correlation and precision medicine.
Knock-in
Knock-in of reporter tags or disease mutations enables tracking of channel localization and function in live cells. For example, tagging hERG with a fluorescent protein allows real-time monitoring of trafficking defects caused by drugs or mutations.
Overexpression
Overexpression of wild-type or mutant channel genes, or of transcription factors like TBX20, can increase channel current density or alter expression levels, helping to dissect regulatory pathways and gain-of-function effects.
How EDITGENE Supports voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization Research
Researchers studying voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization-related genes often need to determine whether a candidate gene is causally involved in repolarization defects, how specific mutations alter channel function, and whether pharmacological interventions can rescue the phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| KCNQ1 Knockout HEK293 Cell Line | EDJ-KQ2359 | Human | 3784 | Details Get a Quote |
| KCND3 Knockout HEK293 Cell Line | EDJ-KQ5023 | Human | 3752 | Details Get a Quote |
| KCNE1 Knockout HEK293 Cell Line | EDJ-KQ5024 | Human | 3753 | Details Get a Quote |
| KCNJ2 Knockout HEK293 Cell Line | EDJ-KQ5032 | Human | 3759 | Details Get a Quote |
| KCNQ1 Knockout HCT 116 Cell Line | EDJ-KQ22798 | Human | 3784 | Details Get a Quote |
| KCNQ1 Knockout HeLa Cell Line | EDJ-KQ22799 | Human | 3784 | Details Get a Quote |
| KCND3 Knockout HeLa Cell Line | EDJ-KQ53706 | Human | 3752 | Details Get a Quote |
| KCNE1 Knockout HeLa Cell Line | EDJ-KQ53707 | Human | 3753 | Details Get a Quote |
| KCNJ2 Knockout HeLa Cell Line | EDJ-KQ53711 | Human | 3759 | Details Get a Quote |
| KCND3 Knockout A-549 Cell Line | EDJ-KQ62184 | Human | 3752 | Details Get a Quote |
| KCNE1 Knockout A-549 Cell Line | EDJ-KQ62185 | Human | 3753 | Details Get a Quote |
| KCNJ2 Knockout A-549 Cell Line | EDJ-KQ62187 | Human | 3759 | Details Get a Quote |
| KCNQ1 Knockout A-549 Cell Line | EDJ-KQ62202 | Human | 3784 | Details Get a Quote |
| KCND3 Knockout HCT 116 Cell Line | EDJ-KQ70669 | Human | 3752 | Details Get a Quote |
| KCNE1 Knockout HCT 116 Cell Line | EDJ-KQ70670 | Human | 3753 | Details Get a Quote |
Frequently Asked Questions About voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization
What is GO:0086008?
GO:0086008 is a Gene Ontology molecular function term describing voltage-gated potassium channel activity that contributes to the repolarization phase of the cardiac muscle cell action potential.
What genes are involved in voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization?
Key genes include KCNH2 (hERG), KCNQ1, KCNA5, KCND3, and their accessory subunits such as KCNE1 and KCNE2.
Why is hERG important for cardiac repolarization?
hERG (Kv11.1) carries the rapid delayed rectifier current IKr, which is critical for phase 3 repolarization; its block by drugs causes long QT syndrome.
How do mutations in KCNQ1 cause long QT syndrome?
Loss-of-function mutations in KCNQ1 reduce the slow delayed rectifier current IKs, delaying repolarization and prolonging the QT interval.
What is the role of Kv1.5 in the heart?
Kv1.5 (KCNA5) conducts the ultrarapid delayed rectifier current, which contributes to atrial repolarization and is a target for atrial fibrillation therapy.
How can CRISPR help study cardiac potassium channels?
CRISPR knockout, point mutation, and knock-in models in cardiomyocytes allow precise dissection of channel function, drug response, and disease mechanisms.
What methods are used to measure voltage-gated potassium channel activity?
Patch-clamp electrophysiology, computational modeling, and action potential recordings in stem cell-derived cardiomyocytes are commonly used.
Which drugs block cardiac potassium channels?
Many drugs, including celecoxib and rosuvastatin, affect hERG, Kv1.5, Kv4.3, and Kv7.1 channels, leading to repolarization abnormalities.
What diseases are linked to GO:0086008 dysfunction?
Long QT syndrome, short QT syndrome, Brugada syndrome, atrial fibrillation, and drug-induced arrhythmias are associated with dysfunction of these channels.
How does TBX20 regulate cardiac repolarization?
TBX20 controls the expression of KCNH2, thereby regulating hERG channel levels and repolarization capacity.
Conclusion
GO:0086008 represents a central molecular function in cardiac electrophysiology, encompassing the voltage-gated potassium channels that drive action potential repolarization. The coordinated activity of hERG, Kv7.1, Kv1.5, Kv4.3, and their regulatory subunits ensures normal heart rhythm, and their dysfunction leads to arrhythmias and drug-induced cardiotoxicity. Advances in CRISPR gene editing and stem cell-derived cardiomyocyte models now allow researchers to dissect the precise contributions of each channel and to test targeted therapies. Continued investigation of this GO term will improve our understanding of cardiac channelopathies and facilitate the development of safer, more effective treatments.
References
- 1. Kratz JM et al.. 2017. Natural products modulating the hERG channel: heartaches and hope.. Nat Prod Rep 34(8):957-980 PMID: 28497823
- 2. Priest BT et al.. 2008. Role of hERG potassium channel assays in drug development.. Channels (Austin) 2(2):87-93 PMID: 18849661
- 3. Wacker S et al.. 2017. Computational Models for Understanding of Structure, Function and Pharmacology of the Cardiac Potassium Channel Kv11.1 (hERG).. Curr Top Med Chem 17(23):2681-2702 PMID: 28413954
- 4. Song Y et al.. 2022. KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation.. Stem Cell Res Ther 13(1):287 PMID: 35765105
- 5. Caballero R et al.. 2017. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.. Proc Natl Acad Sci U S A 114(3):E416-E425 PMID: 28049825
- 6. Yue L et al.. 1996. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization.. J Physiol 496 ( Pt 3)(Pt 3):647-62 PMID: 8930833
- 7. Feng PF et al.. 2019. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane.. Mol Pharm 16(4):1477-1488 PMID: 30807184
- 8. Macías A et al.. 2010. Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials.. J Mol Cell Cardiol 49(6):984-92 PMID: 20858500
